dChan
Anonymous ID: c50a26 Dec. 13, 2019, 11:47 a.m. No.7498639   🗄️.is 🔗kun

Modi-Abe summit postponed amid protests over citizenship bill

 

NEW DELHI – Massive protests in India's northeast against a controversial citizenship bill have forced Japan and India to postpone a summit between Prime Minister Narendra Modi and his counterpart, Shinzo Abe, scheduled for Dec. 15-17. Separately, Bangladesh Foreign Minister A. K. Abdul Momen canceled his Dec. 12-14 visit to India amid concerns over the ongoing situation in the country, even though the Indian government said the Muslim-majority neighbor's decision was taken due to changes in "his program on account of domestic issues."

 

India's Ministry of External Affairs on Friday clarified that the annual Modi-Abe summit had been postponed. Spokesperson Raveesh Kumar said in a statement: "With reference to the proposed visit of Japanese [Prime Minister] Abe to India, both sides have decided to defer the visit to a mutually convenient date in the near future."

 

Guwahati, the capital of the state of Assam, was slated to host Abe's summit with Modi on Monday, though the meeting place had not been officially announced. On early Friday, sources in Abe's government told Nikkei that they were coordinating plans to cancel his India visit. Parts of Assam and neighboring regions have seen major agitation following parliament's approval of the bill, which would grant citizenship to Hindus, Christians, Sikhs and members of three other minority religious groups who have fled to India to escape persecution in Muslim-majority Pakistan, Afghanistan and Bangladesh. Assamese people, whose state borders Bangladesh, fear that granting citizenship to illegal migrants from the neighboring country would threaten their culture and language. TV footage showed thousands of people taking to the streets of Guwahati, shouting slogans against the bill and burning tires. There were also reports that two people were shot dead by police.

 

Many Indians also view the bill as anti-Muslim, as it seeks to offer citizenship on the basis of religion, but excludes. India's population of 1.3 billion is around 80% Hindu and 15% Muslim, with other faiths making up the rest. The country has a tradition of secularism and the constitution guarantees fundamental equality to all people.

 

On Thursday, Modi accused the opposition Indian National Congress of misleading the country on the citizenship bill and fomenting trouble in the northeast. "We are working for [the development] of the northeastern region. We want it to be the growth engine" of the country, he said. "It is well known that those minorities who chose to make Pakistan, Bangladesh and Afghanistan their home had to constantly live in the fear of extinction. This amended legislation by [the] Modi [government] will allow India to extend them dignity and an opportunity to rebuild their lives," tweeted Home Minister Amit Shah.

 

However, many see the latest move by Modi, whose Hindu nationalist Bharatiya Janata Party leads the government, as a violation of the constitution. "It's not [part of] India's culture, ethos and political ethics to enact such a law," said Narayan Bareth, a political analyst based in India's northwestern state of Rajasthan, which borders Pakistan. "It is not according to the spirit of our constitution."

 

"The country has the right to deny [or grant] citizenship to anybody, but it has now been underlined that [decisions will be on the basis of] religion, which is unfortunate," he said, dismissing the bill as an electoral ploy aimed at keeping Hindus loyal to the BJP.

 

The ruling party was returned to power for another five-year term in May, but lost in a recent state election.

https://asia.nikkei.com/Politics/International-relations/Modi-Abe-summit-postponed-amid-protests-over-citizenship-bill

Anonymous ID: c50a26 Dec. 13, 2019, 12:13 p.m. No.7498798   🗄️.is 🔗kun   >>8966 >>9012

Madrigal Pharmaceuticals sold by Bay City Capital: $126.56m-Dec 13

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Number of employees : 17 people.

 

Secondary offering via Goldman Sachs

MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Entry into a Material Definitive Agreement

On December 10, 2019, Madrigal Pharmaceuticals, Inc. (the "Company") and investment funds affiliated with Bay City Capital LLC (the "Selling Stockholders"), entered into an Underwriting Agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC (the "Underwriter"), for the sale by the Selling Stockholders of 1,200,000 shares of common stock of the Company, $0.0001 par value per share (the "Common Stock"), at the public offering price of $107.85 per share. Pursuant to the terms of the Underwriting Agreement, the Selling Stockholders granted the Underwriter a 30-day option to purchase up to 180,000 additional shares, at the public offering price, less the underwriting discount, from the Selling Stockholders.

The closing of the sale of the Common Stock is expected to occur on December 13, 2019, subject to the satisfaction of customary closing conditions. The Company will not receive any proceeds from the sale of the Common Stock by the Selling Stockholders.

https://www.marketscreener.com/MADRIGAL-PHARMACEUTICALS-30340910/news/MADRIGAL-PHARMACEUTICALS-INC-Entry-into-a-Material-Definitive-Agreement-Financial-Statements-an-29721272/

https://www.marketscreener.com/MADRIGAL-PHARMACEUTICALS-30340910/company/

https://www.finviz.com/insidertrading.ashx?oc=1288452&tc=7&b=2